Image Contrast, Image Pre-Processing, and T
MRI
intraclass correlation coefficient
liver metastases
radiomics
repeatability
repeatability coefficient
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jan 2021
11 Jan 2021
Historique:
received:
07
12
2020
revised:
01
01
2021
accepted:
05
01
2021
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
Imaging biomarkers require technical, biological, and clinical validation to be translated into robust tools in research or clinical settings. This study contributes to the technical validation of radiomic features from magnetic resonance imaging (MRI) by evaluating the repeatability of features from four MR sequences: pre-contrast T1- and T2-weighted images, pre-contrast quantitative T1 maps (qT1), and contrast-enhanced T1-weighted images. Fifty-one patients with colorectal cancer liver metastases were scanned twice, up to 7 days apart. Repeatability was quantified using the intraclass correlation coefficient (ICC) and repeatability coefficient (RC), and the impact of non-Gaussian feature distributions and image normalisation was evaluated. Most radiomic features had non-Gaussian distributions, but Box-Cox transformations enabled ICCs and RCs to be calculated appropriately for an average of 97% of features across sequences. ICCs ranged from 0.30 to 0.99, with volume and other shape features tending to be most repeatable; volume ICC > 0.98 for all sequences. 19% of features from non-normalised images exhibited significantly different ICCs in pair-wise sequence comparisons. Normalisation tended to increase ICCs for pre-contrast T1- and T2-weighted images, and decrease ICCs for qT1 maps. RCs tended to vary more between sequences than ICCs, showing that evaluations of feature performance depend on the chosen metric. This work suggests that feature-specific repeatability, from specific combinations of MR sequence and pre-processing steps, should be evaluated to select robust radiomic features as biomarkers in specific studies. In addition, as different repeatability metrics can provide different insights into a specific feature, consideration of the appropriate metric should be taken in a study-specific context.
Identifiants
pubmed: 33440685
pii: cancers13020240
doi: 10.3390/cancers13020240
pmc: PMC7826650
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancer Research UK
ID : C19221/A28683
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C19221/A22746
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/A18083
Pays : United Kingdom
Références
Med Phys. 2020 Sep;47(9):4265-4280
pubmed: 32615647
Phys Med Biol. 2020 Jul 20;:
pubmed: 32688357
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Stat Methods Med Res. 2015 Feb;24(1):27-67
pubmed: 24919831
Eur Radiol. 2020 Nov;30(11):6241-6250
pubmed: 32483644
Magn Reson Med. 2020 Jun;83(6):2293-2309
pubmed: 31703155
Lung Cancer. 2020 Aug;146:197-208
pubmed: 32563015
PLoS One. 2019 Jul 22;14(7):e0219854
pubmed: 31329615
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Cancers (Basel). 2020 Oct 07;12(10):
pubmed: 33036490
Radiology. 2015 Dec;277(3):813-25
pubmed: 26267831
Phys Med Biol. 2019 Apr 12;:
pubmed: 30978707
Med Image Anal. 2011 Apr;15(2):267-82
pubmed: 21233004
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186
pubmed: 27725679
Eur J Radiol. 2018 Apr;101:184-190
pubmed: 29571795
Magn Reson Med. 2019 Jan;81(1):454-465
pubmed: 30159953
BMC Med Res Methodol. 2014 Nov 22;14:121
pubmed: 25417040
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Eur J Radiol. 2019 Jan;110:22-29
pubmed: 30599864
Magn Reson Med. 2021 Mar;85(3):1713-1726
pubmed: 32970859
Magn Reson Med. 1999 Dec;42(6):1072-81
pubmed: 10571928
Med Image Anal. 2006 Apr;10(2):234-46
pubmed: 16307900
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
IEEE Trans Med Imaging. 2000 Feb;19(2):143-50
pubmed: 10784285
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1143-1158
pubmed: 30170872
Transl Oncol. 2009 Dec;2(4):231-5
pubmed: 19956383
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Radiother Oncol. 2019 Jan;130:2-9
pubmed: 30416044
Neuroimage Clin. 2014 Aug 15;6:9-19
pubmed: 25379412
Sci Rep. 2019 Jul 1;9(1):9441
pubmed: 31263116
J Strength Cond Res. 2005 Feb;19(1):231-40
pubmed: 15705040
Sci Rep. 2020 Jun 24;10(1):10248
pubmed: 32581221
Magn Reson Imaging. 1987;5(3):201-8
pubmed: 3626789
Neuro Oncol. 2018 May 18;20(6):848-857
pubmed: 29036412
Radiology. 2017 Aug;284(2):552-561
pubmed: 28481194
Sci Rep. 2019 Mar 18;9(1):4800
pubmed: 30886309
Nat Commun. 2018 Nov 7;9(1):4672
pubmed: 30405103
Elife. 2017 Sep 06;6:
pubmed: 28876221
Radiother Oncol. 2019 Jun;135:107-114
pubmed: 31015155
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929